Product Description
ACI-12589, a PET tracer, shows promise as patient brain scans indicate the signal specificity for a-syn in MSA patients versus healthy volunteers and patients with other a-synucleinopathies. (Sourced from: https://ir.acimmune.com/news-releases/news-release-details/ac-immune-reports-first-live-images-alpha-synuclein-human-brain)
Mechanisms of Action: Imaging Agent
Novel Mechanism: No
Modality: Diagnostic Agent
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AC Immune
Company Location: 1015 LAUSANNE V8 00000
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Dementia|Lewy Body Dementia|Lewy Body Disease|Multiple System Atrophy|Parkinson's Disease|Shy-Drager Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| NCT06445465 | P1 |
Completed |
Dementia|Parkinson's Disease|Shy-Drager Syndrome|Lewy Body Disease|Lewy Body Dementia|Multiple System Atrophy |
2024-11-26 |
12% |
2025-02-20 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
10/27/2023 |
News Article |
AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic |
|
08/04/2023 |
News Article |
AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update |
|
07/03/2023 |
News Article |
AC Immune Showcasing Precision Medicine Programs at AAIC 2023 |
|
07/03/2023 |
News Article |
AC Immune Showcasing Precision Medicine Programs at AAIC 2023 |